Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00004670
DRKS00004670
Recruiting
Not Applicable

Ambulant sleep stage analysis with simply measureable physiological parameters

Abteilung PneumologieUniversitätsklinikum Freiburg0 sites60 target enrollmentJanuary 24, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy subjectsG47.31G47.8Other sleep disorders

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy subjects
Sponsor
Abteilung PneumologieUniversitätsklinikum Freiburg
Enrollment
60
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 24, 2013
End Date
July 31, 2013
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Abteilung PneumologieUniversitätsklinikum Freiburg

Eligibility Criteria

Inclusion Criteria

  • •minimum age of 18 years, maximum of 40 patients with sleep associated disease, minimum of 20 healthy subjects

Exclusion Criteria

  • •minimum age of 18 years, maximum of 40 patients with sleep associated disease, minimum of 20 healthy subjects

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
A clinical study to Evaluate The Safety, Tolerability And Immunogenicity Of Three Formulations (15µg Without Adjuvant, 7.5µg With Adjuvant And 3.75µg With Adjuvant) Of Monovalent H1N1 Influenza A (2009) Virus Vaccine In Healthy Adults.
CTRI/2010/091/000028Panacea Biotec Ltd72
Active, not recruiting
Not Applicable
A phase IIa randomised, observer-blind, comparative study of the efficacy, tolerability and consumer acceptability of topical MedSpray™ TP 1 % versus Lamisil® Once 1 % in the treatment of tinea pedis - Tinea Pedistinea pedisMedDRA version: 9.1Level: LLTClassification code 10043873Term: Tinea pedis
EUCTR2008-002399-92-DEMedPharm Ltd.
Completed
Phase 2
Safety, Reactogenicity and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
CTRI/2011/12/002233ovartis Vaccine Institute for Global Health200
Unknown
Not Applicable
A Study to assess the Safety and Immunogenicity of the MAlaria Vaccine, R1, With Matrix-M1 AdjuvantMalaria
PACTR201610001813366Oxford University24
Not yet recruiting
Phase 3
A randomised, controlled, observer-blinded phase III clinical trial to compare the effect of intravenous ferric carboxymaltose to placebo on exercise capacity and cardiac function in patients with chronic heart failure and iron deficiency - EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac function in patients with iron deficiencY and chronic Heart Failure
NL-OMON32525Vifor Pharma - Vifor International AG60